Olaussen, Ken A.
Inserm · Université Paris-Saclay · Institut Gustave Roussy
3 papers on CoChatORCID 0000-0002-3115-8914
Most cited papers
- Verified
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment
Cited by 321
- Verified
A Novel Epidermal Growth Factor Receptor Inhibitor Promotes Apoptosis in Non–Small Cell Lung Cancer Cells Resistant to Erlotinib
de La Motte Rouge, T., Galluzzi, L., Olaussen, K. A., Zermati, Y., Tasdemir, E., Robert, T., Ripoche, H., Lazar, V., Dessen, P., Harper, F., et al. (2007) · Cancer Research
Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research
Cited by 141
- Verified
Inhibition of Chk1 Kills Tetraploid Tumor Cells through a p53-Dependent Pathway
Vitale, I., Galluzzi, L., Vivet, S., Nanty, L., Dessen, P., Senovilla, L., Olaussen, K. A., Lazar, V., Prudhomme, M., Golsteyn, R. M., et al. (2007) · PLoS ONE
Microtubule and mitosis dynamicsCancer-related Molecular Pathways
Cited by 77
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free